-

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 31 March 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:

Eurofins Scientific SE (Paris:ERF):

ANNEXE B

Form to be used for the disclosure of the total number of voting rights and capital, in accordance with the law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedi (including the issuer ID allocated by the CSSF)

EUROFINS SCIENTIFIC SE – E1013

2. Identity of the notifier (if another person makes the notification on behalf of the issuer) N/A

3. Total number of shares composing the share capital of the notifying issuer 176,000,000

4. Total number of voting rights attached to the shares composing the share capital of the notifying issuer, including the suspended voting rightsii

365,011,719

5. Origin of the changeiii

  • Reduction in number of shares:
    • Cancellation of 6,163,000 shares
  • Reduction in numbers of voting rights:
    • Cancellation of some class A beneficiary units
    • Purchase of treasury shares as part of the Company’s share buyback programme

6. Date when the change occurred

31 March 2026

i Either the full name of the legal entity or another method for identifying the issuer or underlying issuer, provided it is reliable and accurate.

ii For further details on the total number of voting rights, please refer to point 1(b) of circular CSSF 08/349.

iii As, for example, a capital increase or reduction.

Contacts

Eurofins Scientific SE

Eurofins Scientific SE

BOURSE:ERF

Release Versions

Contacts

Eurofins Scientific SE

More News From Eurofins Scientific SE

Eurofins Makes Significant Progress in H1 2026 Towards Its Mid-Term 2027 Objectives, With 130bps of Adjusted EBITDA Margin Expansion, Strong Cash Conversion, and 29% EPS Growth

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Financial highlights in H1 2026 Basic EPS8 grew 29% to €1.55 in H1 2026 vs €1.20 in H1 2025, as Eurofins continued to accumulate the operational benefits from the five-year investment programme in its hub and spoke network of laboratories and digitalisation initiatives. Revenues of €3,701m increased by 2.5% as reported including a 2.9% headwind from foreign currency, and 2.7% organically13. Organic growth13 improved as the half...

Eurofins Scientific SE: Weekly Report on Share Repurchases from 13th July to 17th July 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Weekly report on share repurchases from 13th July to 17th July 2026   Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 13/07/2026 FR0014000MR3 15 000 69.1984 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 13/07...

Eurofins Agrees to Acquire Element Materials Technology’s Life Sciences Testing Services Business in North America

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific (EUFI.PA) (Paris:ERF), a global scientific leader in bioanalytical testing, has reached an agreement with Element Materials Technology (“Element”) to acquire its Life Sciences Testing Services business in North America, for an enterprise value of $400m. The transaction is subject to customary conditions, including regulatory approvals, and is expected to close in Q4 2026. Element’s North America Life Sciences Testing Services inc...
Back to Newsroom